ASP 8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer-Reference-Cited by-同舟云学术

ASP 8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer

Published:2018-06-29 Issue:8 Volume:109 Page:2532-2538
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Azuma Koichi¹^ORCID,Nishio Makoto²,Hayashi Hidetoshi³,Kiura Katsuyuki⁴,Satouchi Miyako⁵,Sugawara Shunichi⁶,Hida Toyoaki⁷^ORCID,Iwamoto Yasuo⁸,Inoue Akira⁹,Takeda Koji¹⁰,Ikeda Satoshi¹¹,Nakagawa Tomoki¹²,Takeda Kentaro¹²,Asahina Seitaro¹³,Komatsu Kanji¹²,Morita Satoshi¹⁴,Fukuoka Masahiro¹⁵,Nakagawa Kazuhiko³

Affiliation:

1. Department of Internal Medicine Kurume University Hospital Fukuoka Japan

2. Department of Thoracic Medical Oncology The Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

3. Department of Medical Oncology Kindai University Hospital Osaka Japan

4. Department of Allergy and Respiratory Medicine Okayama University Hospital Okayama Japan

5. Department of Thoracic Oncology Hyogo Cancer Center Hyogo Japan

6. Department of Pulmonary Medicine Sendai Kousei Hospital Miyagi Japan

7. Department of Thoracic Oncology Aichi Cancer Center Hospital Aichi Japan

8. Department of Respiratory Medicine Hiroshima City Hospital Hiroshima Japan

9. Clinical Research Innovation, and Education Center Tohoku University Hospital Miyagi Japan

10. Department of Clinical Oncology Osaka City General Hospital Osaka Japan

11. Department of Respiratory Medicine kanagawa Cardiovascular and Respiratory Center Kanagawa Japan